COVID-19 Vaccine |
1 |
1 |
Heart |
0 |
0.78 |
Vaccines |
0 |
0.65 |
Coronary Artery Disease (CAD) |
0 |
0.63 |
Heart Failure (HF) |
0 |
0.62 |
Influenza |
0 |
0.58 |
Patient Safety |
0 |
0.57 |
Cardiovascular Risk Management |
0 |
0.54 |
Cardiomyopathy |
0 |
0.44 |
Immunization |
0 |
0.42 |
Atrial Fibrillation |
0 |
0.38 |
COVID-19 |
0 |
0.35 |
Influenza Vaccine |
0 |
0.35 |
Adverse Effects |
0 |
0.26 |
Europe |
0 |
0.26 |
Myocarditis |
0 |
0.16 |
Thromboembolism |
0 |
0.13 |
Hospital |
0 |
0.1 |
Venous Thromboembolism (VTE) |
0 |
0.1 |
Pediatric Respiratory Infections |
0 |
0.06 |
Cancer |
0 |
0.05 |
Cardiovascular disease |
0 |
0.05 |
Centers for Disease Control and Prevention |
0 |
0.05 |
Child |
0 |
0.05 |
Geriatrics |
0 |
0.05 |
Match |
0 |
0.05 |
Measles |
0 |
0.05 |
Pandemic |
0 |
0.05 |
Pericarditis |
0 |
0.05 |
Mechanical Ventilation |
0 |
0.03 |